Several studies have examined HE4 expression in both blood and tumor tissues, suggesting its potential as a diagnostic and prognostic biomarker in breast cancer [13,14,15,16,17,18,19,20,21,22]. This evidence concerns the gene WFDC2 and breast carcinoma.